Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies49
  • 7D6.2%
  • 3M9.0%
  • 1Y28.5%
  • YTD14.4%

Over the last 7 days, the Biotech industry has risen 2.0%, driven by gains from Swedish Orphan Biovitrum of 4.5%. Meanwhile, Diamyd Medical actually underperformed within the industry, shrinking 18% in the last week. This takes the industry's 12 month performance to a gain of 28%. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026SEK 238.1bSEK 38.5b-SEK 5,654,944,191.9718.6x-42.1x6.2x
Fri, 13 Mar 2026SEK 218.6bSEK 38.5b-SEK 5,720,096,494.5817.3x-38.2x5.7x
Sun, 08 Feb 2026SEK 223.2bSEK 38.6b-SEK 5,517,310,484.4427.2x-40.5x5.8x
Tue, 06 Jan 2026SEK 206.6bSEK 38.1b-SEK 556,373,959.9133.8x-371.4x5.4x
Thu, 04 Dec 2025SEK 204.2bSEK 38.1b-SEK 568,055,290.8231.8x-359.5x5.4x
Sat, 01 Nov 2025SEK 206.4bSEK 37.3b-SEK 1,198,953,801.4338.8x-172.2x5.5x
Mon, 29 Sep 2025SEK 192.5bSEK 36.4bSEK 3.0b31x63.6x5.3x
Wed, 27 Aug 2025SEK 198.2bSEK 36.1bSEK 2.8b30.7x70.3x5.5x
Fri, 25 Jul 2025SEK 193.2bSEK 35.9bSEK 2.8b28.8x69.2x5.4x
Sun, 22 Jun 2025SEK 179.0bSEK 35.2bSEK 2.2b28.1x80.3x5.1x
Tue, 20 May 2025SEK 193.8bSEK 33.9bSEK 1.2b34.8x161.3x5.7x
Thu, 17 Apr 2025SEK 175.2bSEK 33.7bSEK 756.5m29.4x231.6x5.2x
Sat, 15 Mar 2025SEK 196.7bSEK 33.7bSEK 579.2m33.2x339.6x5.8x
Mon, 10 Feb 2025SEK 220.8bSEK 33.7bSEK 271.3m56.5x814.1x6.6x
Wed, 08 Jan 2025SEK 222.5bSEK 33.0b-SEK 4,418,607,133.09161.4x-50.4x6.7x
Fri, 06 Dec 2024SEK 211.2bSEK 33.0b-SEK 4,445,339,784.56145x-47.5x6.4x
Sun, 03 Nov 2024SEK 215.9bSEK 33.2b-SEK 4,482,059,813.14138.3x-48.2x6.5x
Tue, 01 Oct 2024SEK 218.7bSEK 31.4b-SEK 5,543,334,290.8352.4x-39.5x7x
Thu, 29 Aug 2024SEK 210.8bSEK 31.4b-SEK 5,438,746,160.8950.7x-38.8x6.7x
Sat, 27 Jul 2024SEK 205.0bSEK 31.4b-SEK 5,423,607,425.0246.9x-37.8x6.5x
Mon, 24 Jun 2024SEK 193.1bSEK 30.6b-SEK 5,516,948,117.3039x-35x6.3x
Wed, 22 May 2024SEK 191.4bSEK 30.6b-SEK 5,500,926,223.4340.4x-34.8x6.3x
Fri, 19 Apr 2024SEK 177.7bSEK 29.8b-SEK 5,266,079,807.9163.7x-33.8x6x
Sun, 17 Mar 2024SEK 186.1bSEK 29.8b-SEK 5,636,600,511.9959.6x-33x6.2x
Tue, 13 Feb 2024SEK 174.2bSEK 29.6b-SEK 5,689,838,434.7960.8x-30.6x5.9x
Thu, 11 Jan 2024SEK 187.9bSEK 28.7b-SEK 1,198,150,867.0059.7x-156.8x6.5x
Sat, 09 Dec 2023SEK 169.9bSEK 28.7b-SEK 1,200,254,628.0058.4x-141.6x5.9x
Mon, 06 Nov 2023SEK 159.4bSEK 28.6b-SEK 1,294,362,402.0049x-123.1x5.6x
Wed, 04 Oct 2023SEK 161.2bSEK 27.4b-SEK 2,016,819,081.0047.9x-80x5.9x
Fri, 01 Sep 2023SEK 154.7bSEK 27.4b-SEK 2,041,245,894.0052.2x-75.8x5.7x
Sun, 30 Jul 2023SEK 156.0bSEK 27.5b-SEK 1,534,283,427.0055.8x-101.7x5.7x
Tue, 27 Jun 2023SEK 160.4bSEK 26.4b-SEK 1,312,502,366.0045.9x-122.2x6.1x
Thu, 25 May 2023SEK 171.9bSEK 26.3b-SEK 1,366,671,495.0045.3x-125.8x6.5x
Sat, 22 Apr 2023SEK 173.8bSEK 25.5b-SEK 2,076,006,783.0039.7x-83.7x6.8x
Price to Earnings Ratio

-83.7x


Total Market Cap: SEK 173.8bTotal Earnings: -SEK 2,076,006,783.00Total Revenue: SEK 25.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -47.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 15% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market5.71%
Healthcare6.07%
Biotech6.17%
Biotech6.17%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 411.004.5%
+SEK 6.2b		54.3%PE297.2x
BONEX Bonesupport HoldingSEK 255.0018.6%
+SEK 2.7b		-20.0%PE119.8x
BIOA B BioArcticSEK 341.808.9%
+SEK 2.5b		96.4%PE29.7x
VITR VitrolifeSEK 103.9010.1%
+SEK 1.3b		-33.4%PS4.1x
BIOG B BioGaiaSEK 120.602.3%
+SEK 273.1m		18.8%PE36.7x

Latest News

VITR
SEK 103.90
Vitrolife
7D
10.1%
1Y
-33.4%

VITR: Governance Amendments And Steady Assumptions Will Support Future Upside

Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.
DMYD B
SEK 1.25
Diamyd Medical
7D
-18.3%
1Y
-83.7%
SPRINT
SEK 4.04
Sprint Bioscience
7D
54.8%
1Y
515.9%
SOBI
SEK 411.00
Swedish Orphan Biovitrum
7D
4.5%
1Y
54.3%
BONEX
SEK 255.00
Bonesupport Holding
7D
18.6%
1Y
-20.0%
BIOA B
SEK 341.80
BioArctic
7D
8.9%
1Y
96.4%

BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook

The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.
BIOG B
SEK 120.60
BioGaia
7D
2.3%
1Y
18.8%

BIOG B: Downgrade And Extra Dividend Will Set Up Future Multiple Re Rating

Analysts have trimmed their stance on BioGaia with a lower SEK price target, reflecting more cautious views on the shares following a downgrade from SEB Equities and only slight adjustments to assumptions such as the discount rate and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the trimmed price target and modest changes to the discount rate and future P/E as leaving room for upside if execution on growth initiatives tracks current expectations.
VICO
SEK 10.34
Vicore Pharma Holding
7D
6.3%
1Y
58.1%
EXPRS2
SEK 3.55
ExpreS2ion Biotech Holding
7D
-37.5%
1Y
-81.9%
ATORX
SEK 0.35
Alligator Bioscience
7D
100.2%
1Y
-94.3%
SUBGEN
SEK 0.10
Subgen AI
7D
-22.6%
1Y
n/a
GEAN
NOK 0.88
Genetic Analysis
7D
-15.4%
1Y
31.3%
PROGEN
SEK 0.81
Prostatype Genomics
7D
-9.0%
1Y
-67.5%
SYNACT
SEK 17.30
SynAct Pharma
7D
-3.4%
1Y
-9.2%
DEX
SEK 7.15
Dextech Medical
7D
-10.6%
1Y
68.6%
RESP
SEK 7.72
Respiratorius
7D
-12.5%
1Y
n/a